1Adler AI, Stevens RJ, Manley SE, et al. Development and pro gression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study[J]. Kidney Int, 2003,63 : 225.
2Gustin C,Delaive E,Dieu M,et al. Upregulation of pentraxin 3 in human endothelial cells after lysophosphatidic acid exposure[J]. Arterioscler Thromb Vasc Biol, 2008,28 (3) : 491.
3Aoki J. Mechanisms of lysophosphatidic acid production [J]. Semin Cell Dev Biol,2004,15(5):477.
4Ristic V,Tepsic V, Ristic Medie D, et al. Plasma and erythrocyte phospholipid fatty acids composition in Serbian hemodialyzed pa tients[J]. Ren Fail,2006,28(3) :211.
6Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment [J]. Semin Dial,2007,20(4) :286.
7王海燕.肾脏病学[M].北京:人民卫生出版社,2008:1948-1949.
8Krasniak A,Drozdz M,Chmiel G, et al. Evaluation of atheroscle rosis progression in patients treated repeatedly with hemodialysis [J]. Przegl Lek,2002,59(8) :606.
5Narehi H. Risk of long term renal impairment and duration offollow up recommended for Henoch-Schonlein purpura withnormal or minimal urinary findings; a systematic review [J].Arch Dis Child,2005,90(9) :916-920.
